Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Carcinogenesis
Diabetes Mellitus
Duodenal Obstruction
Gallbladder Diseases
Gastric Mucosa
/ metabolism
Humans
Infant, Newborn
Intestinal Atresia
/ genetics
Kelch-Like ECH-Associated Protein 1
NF-E2-Related Factor 2
Neoplasms
Phosphatidylinositol 3-Kinases
Regulatory Factor X Transcription Factors
/ genetics
Transcriptome
Case report
Duodenal atresia
Heterotopic gastric mucosa
Mitchell–Riley syndrome
RFX6
Transcriptomic profile
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
29 10 2021
29 10 2021
Historique:
received:
29
04
2021
accepted:
17
10
2021
entrez:
30
10
2021
pubmed:
31
10
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Homozygous mutations in the transcription factor RFX6 are the cause of the Mitchell-Riley syndrome (MRS) associating neonatal diabetes, congenital digestive system, such as biliary atresia, pancreatic hypoplasia, duodenal and/or jejunal atresia, intestinal malrotation, gallbladder aplasia, cholestasis. A constitutive inactivation of RFX6 leads also to gastric heterotopia. Application of RNA-seq in human diseases may help to better understand pathogenic mechanism of diseases and to predict the risk of developing chronic disorders and personalizing their prevention and treatment. We evaluated oncogenic patterns and cancer predisposition using the transcriptomic profile in a case of MRS with neonatal diabetes, duodenal atresia, and extensive intestinal tract gastric heterotopia. We signalled the interactors of RFX6 with other up and downregulated genes, that may be interested in severity of diabetic condition, in multi-organs impairment and cancer predisposition. Furthermore, several dysregulated genes are involved in biological processes that can lead to promote cancer including "Evading apoptosis" (BAD, BBC3, EGF, FGFR2, FLT3LG, HMOX1, HRAS, IFNAR2, IGF1R, IL12RB1, IL13RA1, IL15, IL2RB, IL2RG, IL6R, KEAP1, MGST1, PDGFA, PDGFRB, PIK3R3, RALB, RALGDS, RASSF1, SOS1, TGFA, TXNRD3), "Proliferation" (APC, BRAF, CCND2, CCND3, CCNE2, FGFR2, FLT3LG, FZD1, FZD6, HMOX1, HRAS, IGF1R, KEAP1, LRP6, MAPK3, MGST1, PDGFA, PDGFB, PDGFRB, RB1, SOS1, TGFA, TXNRD3, WNT10B), "Sustained angiogenesis" (BRAF, FGFR2, FLT3LG, HRAS, IGF1R, JAG1, MAPK3, NOTCH2, PDGFA, PDGFB, PDGFRB, SOS1, TGFA, TGFB1), "Genomic instability" (BAD, BBC3) and "Insensitivity to anti-growth signals" (SMAD2, TGFB1). We also inspected the signalings and their related genes in cancer, such as "PI3K signaling", "ERK signaling", "JAK-STAT signaling", "Calcium signaling", "Other RAS signaling", "WNT signaling". In our MRS patient, we signaled the interactors of RFX6 with other up- and downregulated genes that may be related to severe diabetic condition, multi-organ impairment, and cancer predisposition. Notably, many dysregulated genes may lead to triggering carcinogenesis. The possibility of the patient developing cancer degeneration in heterotopic gastric mucosa and/or additional long-term tumoral sequelae is not excluded. Personalized prevention and treatment strategies should be proposed.
Sections du résumé
BACKGROUND
Homozygous mutations in the transcription factor RFX6 are the cause of the Mitchell-Riley syndrome (MRS) associating neonatal diabetes, congenital digestive system, such as biliary atresia, pancreatic hypoplasia, duodenal and/or jejunal atresia, intestinal malrotation, gallbladder aplasia, cholestasis. A constitutive inactivation of RFX6 leads also to gastric heterotopia. Application of RNA-seq in human diseases may help to better understand pathogenic mechanism of diseases and to predict the risk of developing chronic disorders and personalizing their prevention and treatment. We evaluated oncogenic patterns and cancer predisposition using the transcriptomic profile in a case of MRS with neonatal diabetes, duodenal atresia, and extensive intestinal tract gastric heterotopia.
RESULTS
We signalled the interactors of RFX6 with other up and downregulated genes, that may be interested in severity of diabetic condition, in multi-organs impairment and cancer predisposition. Furthermore, several dysregulated genes are involved in biological processes that can lead to promote cancer including "Evading apoptosis" (BAD, BBC3, EGF, FGFR2, FLT3LG, HMOX1, HRAS, IFNAR2, IGF1R, IL12RB1, IL13RA1, IL15, IL2RB, IL2RG, IL6R, KEAP1, MGST1, PDGFA, PDGFRB, PIK3R3, RALB, RALGDS, RASSF1, SOS1, TGFA, TXNRD3), "Proliferation" (APC, BRAF, CCND2, CCND3, CCNE2, FGFR2, FLT3LG, FZD1, FZD6, HMOX1, HRAS, IGF1R, KEAP1, LRP6, MAPK3, MGST1, PDGFA, PDGFB, PDGFRB, RB1, SOS1, TGFA, TXNRD3, WNT10B), "Sustained angiogenesis" (BRAF, FGFR2, FLT3LG, HRAS, IGF1R, JAG1, MAPK3, NOTCH2, PDGFA, PDGFB, PDGFRB, SOS1, TGFA, TGFB1), "Genomic instability" (BAD, BBC3) and "Insensitivity to anti-growth signals" (SMAD2, TGFB1). We also inspected the signalings and their related genes in cancer, such as "PI3K signaling", "ERK signaling", "JAK-STAT signaling", "Calcium signaling", "Other RAS signaling", "WNT signaling".
CONCLUSIONS
In our MRS patient, we signaled the interactors of RFX6 with other up- and downregulated genes that may be related to severe diabetic condition, multi-organ impairment, and cancer predisposition. Notably, many dysregulated genes may lead to triggering carcinogenesis. The possibility of the patient developing cancer degeneration in heterotopic gastric mucosa and/or additional long-term tumoral sequelae is not excluded. Personalized prevention and treatment strategies should be proposed.
Identifiants
pubmed: 34715892
doi: 10.1186/s13023-021-02093-9
pii: 10.1186/s13023-021-02093-9
pmc: PMC8556982
doi:
Substances chimiques
Kelch-Like ECH-Associated Protein 1
0
NF-E2-Related Factor 2
0
Regulatory Factor X Transcription Factors
0
PIK3R3 protein, human
EC 2.7.1.137
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
455Informations de copyright
© 2021. The Author(s).
Références
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Trends Cancer. 2020 Jan;6(1):6-9
pubmed: 31952782
J Clin Res Pediatr Endocrinol. 2016 Jun 5;8(2):246-9
pubmed: 26761945
J Gastroenterol Hepatol. 2006 Feb;21(2):483-4
pubmed: 16509885
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
Am J Gastroenterol. 2004 Mar;99(3):543-51
pubmed: 15056100
Zhonghua Er Ke Za Zhi. 2020 Jan 2;58(1):62-64
pubmed: 31905482
PLoS One. 2017 Jun 8;12(6):e0179006
pubmed: 28594943
Case Rep Genet. 2015;2015:937201
pubmed: 26770845
Nephron Physiol. 2009;111(3):p39-53
pubmed: 19276629
Nat Commun. 2019 Mar 29;10(1):1415
pubmed: 30926791
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Korean Surg Soc. 2011 Jun;80 Suppl 1:S6-S11
pubmed: 22066087
Mol Cell Endocrinol. 2017 Aug 15;451:1-14
pubmed: 28576744
Pediatr Diabetes. 2014 Feb;15(1):67-72
pubmed: 23914949
Acta Chir Belg. 2014 Jan-Feb;114(1):79-81
pubmed: 24720145
Cells. 2020 Oct 16;9(10):
pubmed: 33081387
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt B):1786-1794
pubmed: 29842892
Pediatr Rep. 2021 Jan 05;13(1):45-56
pubmed: 33466296
Acta Pathol Jpn. 1979 May;29(3):347-50
pubmed: 452898
Oncogene. 2012 Aug 2;31(31):3647-54
pubmed: 22120711
Trends Mol Med. 2018 Jan;24(1):85-101
pubmed: 29217119
J Appl Genet. 2017 Feb;58(1):71-78
pubmed: 27311313
Front Pediatr. 2019 Jun 18;7:243
pubmed: 31275908
Sci Rep. 2016 May 11;6:25765
pubmed: 27166427
Tuberculosis (Edinb). 2017 Dec;107:48-58
pubmed: 29050771
Brief Bioinform. 2018 Mar 1;19(2):286-302
pubmed: 27881428
Int J Mol Sci. 2020 Aug 25;21(17):
pubmed: 32854418
Mol Metab. 2019 Nov;29:24-39
pubmed: 31668390
Theranostics. 2020 Aug 29;10(24):10940-10956
pubmed: 33042263
Eur J Hum Genet. 2015 Dec;23(12):1744-8
pubmed: 26264437
Dig Liver Dis. 2012 Apr;44(4):292-6
pubmed: 22222950
Carcinogenesis. 2014 Jul;35(7):1547-55
pubmed: 24451147
Oncotarget. 2017 May 25;8(34):56768-56779
pubmed: 28915629
Colomb Med (Cali). 2012 Sep 30;43(3):235-43
pubmed: 24893199
Epidemiol Prev. 2018 May-Aug;42(3-4 Suppl 1):1-34
pubmed: 30066535
Dev Biol. 2011 Mar 1;351(1):135-45
pubmed: 21215266
Eur J Med Genet. 2016 Sep;59(9):429-35
pubmed: 27523286
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Biol Chem. 2004 Sep 17;279(38):40062-75
pubmed: 15247266
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):51-57
pubmed: 28238732
Indian J Gastroenterol. 1997 Oct;16(4):157-8
pubmed: 9357194
Nat Med. 2020 Feb;26(2):236-243
pubmed: 31959990
Med Sci (Paris). 2016 Jan;32(1):15-20
pubmed: 26850602
Stem Cell Res Ther. 2020 Oct 29;11(1):459
pubmed: 33121533
Pediatr Diabetes. 2014 Jun;15(4):313-8
pubmed: 24168455
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Cilia. 2016 Jun 10;5:14
pubmed: 27293550
Apoptosis. 2002 Aug;7(4):335-45
pubmed: 12101393
Radiother Oncol. 2018 Mar;126(3):450-464
pubmed: 29054375
DNA Repair (Amst). 2016 Feb;38:94-101
pubmed: 26704428
Breast Cancer Res. 2010;12(5):R85
pubmed: 20946665
J Clin Pathol. 2020 Sep;73(9):527-530
pubmed: 32699115
Biochem J. 2007 Feb 1;401(3):679-88
pubmed: 17037982